Intellia.jpg
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
November 22, 2021 07:30 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) --  Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has...
Intellia.jpg
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
June 04, 2021 07:30 ET | Intellia Therapeutics, Inc.
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidateLate-breaking abstract selected for oral presentation on...
Intellia.jpg
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET | Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
Intellia.jpg
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
March 30, 2021 07:30 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
logo long.jpg
Global CNS Specific Antisense Oligonucleotide Market to Surpass US$ 6.8 Billion by 2026 – Coherent Market Insights
February 08, 2019 08:30 ET | CMI
SEATTLE, Feb. 08, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CNS specific antisense oligonucleotide market is valued at US$ 883.7 million in 2017, and is projected to...